by Madaline Spencer | Jan 9, 2026
The U.S. Food and Drug Administration (FDA) has approved Cablivi (caplacizumab) for the treatment of pediatric patients ages 12 years and older with acquired thrombotic thrombocytopenic purpura (aTTP) in combination with plasma exchange and immunosuppressive therapy. ...
by Madaline Spencer | Jan 9, 2026
Vicki Salemi, Career Expert, discusses current trends in the healthcare job market and expectations for 2026. Recent data from the 2025 Monster Healthcare Market Report shows how the healthcare industry is changing. Through an analysis of healthcare job...
by Madaline Spencer | Jan 8, 2026
Jun Ho Jang, MD, PhD, Professor, Division of Hematology-Oncology at Samsung Medical Center, discusses results from an open-label extension study testing pozelimab plus cemdisiran combination therapy in patients with paroxysmal nocturnal hemoglobinuria (PNH), who...
by Madaline Spencer | Jan 7, 2026
The U.S. Food and Drug Administration (FDA) has approved Aqvesme (mitapivat) for the treatment of anemia in adults with alpha- or beta-thalassemia. Alpha- and beta-thalassemia are blood disorders that reduce the body’s production of hemoglobin. Affected people...
by Madaline Spencer | Jan 7, 2026
Ciro Rinaldi, MD, Consultant Hematologist and Professor of Hematology at United Lincolnshire Hospital, discusses treatment with elritercept for patients with myelofibrosis (MF). MF is characterized by the buildup of scar tissue in the bone marrow. The...
